Prognosis Related to Induced Thrombopenia With Heparin Under Venoarterial ECMO in Reanimation

Thrombocytopenia is a frequent and serious adverse event in patients treated with veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock. Similarly to postcardiac surgery patients, heparin-induced thrombocytopenia (HIT) could represent the causative underlying mechanism. However, the epidemiology as well as related mortality regarding HIT and VA-ECMO remains largely unknown. The investigators aimed to define the prevalence and associated 90-day mortality of HIT diagnosed under VA-ECMO.This retrospective study included patients under VA-ECMO from 20 French centers between 2012 and 2016.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heparin-Induced Thrombocytopenia

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years
Patient hospitalized in intensive care for a cardiovascular failure requiring the setting up of an ECMO-VA
ECMO-VA duration ≥ 3 days
HIT confirmed by immunological tests
Patient affiliated to a Social Security scheme

Exclusion criteria

Known antecedent of TIH prior to cannulation
Pregnant woman
ECMO-VA following cardiopulmonary arrest or septic shock

Treatment and study plan

Hospitalization for more than 3 days with high clinical suspicion of HIT and positive anti-PF4/heparin antibodies

Other

Patients are classified according to results of functional tests as having either Confirmed or Excluded HIT.

Primary outcomes

Death

Time frame: 90 days after inclusion

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: TIH ECMO

Important dates

Study start: 2016
Primary completion: 2018
Study completion: 2018
First posted: Jun 7, 2019
Registry last updated: Jun 7, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed